What Mosaic Immunoengineering Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Garnick Robert L | Director | Jan 29 | Derivative Conversion · C | +356,794 | — | — | 356,794 |
| Lytle Paul J | EVP, Chief Financial Officer | Jan 29 | Derivative Conversion · C | +1,641,252 | — | — | 1,641,252 |
| Steinmetz Nicole Franziska | Acting CSO | Jan 29 | Derivative Conversion · C | +570,870 | — | — | 570,870 |
| Steinmetz Nicole Franziska | Acting CSO | Jan 29 | Derivative Conversion · C | +1,641,252 | — | — | 1,641,252 |
| King Steven W | President and CEO | Jan 29 | Derivative Conversion · C | +1,641,252 | — | — | 1,641,252 |
| Flowers Clifford L | CFO and Interim CEO | Apr 17 | Exercise / conversion · M | +75,000 | $0.10 | +$7.5K | 75,000 |
| Felcyn Gloria | Director | Apr 30 | Grant / award · A | +48,200 | $0.10 | +$4.82K | 951,690 |
| Felcyn Gloria | Director | Apr 27 | Grant / award · A | +4,500 | $0.10 | +$450 | 903,490 |
| Felcyn Gloria | Director | Apr 26 | Grant / award · A | +89,290 | $0.10 | +$8.93K | 898,990 |
| Falk Helmut Jr | Director | Dec 09 | Exercise / conversion · M | +100,000 | $0.07 | +$7.45K | 2,622,731 |
| Falk Helmut Jr | Director | Oct 27 | Open-market sale · S | −25,000 | $0.30 | −$7.5K | 2,522,731 |
| Bibeau Paul R | VP, Business Development | Apr 15 | Open-market buy · P | +100,000 | $0.10 | +$9.5K | 400,000 |
| Bibeau Paul R | VP, Business Development | Jan 30 | Open-market buy · P | +2,000 | $0.11 | +$220 | 300,000 |
| Bibeau Paul R | VP, Business Development | Jan 30 | Open-market buy · P | +98,000 | $0.12 | +$11.3K | 298,000 |
| Johnson Carlton M | Director | Nov 26 | Open-market buy · P | +63,200 | $0.11 | +$7.02K | 525,000 |
| Johnson Carlton M | Director | Nov 26 | Open-market buy · P | +30,000 | $0.11 | +$3.42K | 461,800 |
| Johnson Carlton M | Director | Nov 26 | Open-market buy · P | +46,800 | $0.12 | +$5.38K | 431,800 |
| Johnson Carlton M | Director | Nov 25 | Open-market buy · P | +10,000 | $0.11 | +$1.14K | 385,000 |
| Bibeau Paul R | VP, Business Development | Nov 21 | Open-market buy · P | +61,720 | $0.12 | +$7.1K | 200,000 |
| Bibeau Paul R | VP, Business Development | Nov 21 | Open-market buy · P | +15,500 | $0.11 | +$1.77K | 138,280 |
Loading...
